-- Salomon Brothers analyst Eli Kammerman said he maintained his hold rating on Bausch & Lomb Inc and maintained estimates of $2.40 per share for 1996 and $2.70 for 1997.
-- believes current stock weakness is due to approval by U.S. Food and Drug Aministration of cochlear implant, seen as improved technology compared to traditional hearing aid, including Bausch's Miracle Ear.
-- sees sales growth from Bausch's Miracle Ear division likely to slow from his estimate of 8 percent annually to 4-6 percent.
-- Bausch shares fell 2-1/2 to 33-1/2.